Los Angeles Capital Management
CHRS icon

Los Angeles Capital Management’s Coherus Oncology CHRS Stock Holding History

Los Angeles Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-131,360
Closed -$223K – 2424
2025
Q4 		$223K Buy
131,360
+43,415
+49% +$63.3K ﹤0.01% 1201
2025
Q3 		$144K Sell
87,945
-299,971
-77% -$334K ﹤0.01% 1307
2025
Q2 		$284K Sell
387,916
-603,597
-61% -$521K ﹤0.01% 1069
2025
Q1 		$800K Sell
991,513
-124,629
-11% -$143K ﹤0.01% 624
2024
Q4 		$1.54M Buy
1,116,142
+186,010
+20% +$209K 0.01% 500
2024
Q3 		$967K Buy
930,132
+720,672
+344% +$988K ﹤0.01% 661
2024
Q2 		$362K Buy
209,460
+13,250
+7% +$26.7K ﹤0.01% 949
2024
Q1 		$469K Buy
196,210
+59,390
+43% +$146K ﹤0.01% 890
2023
Q4 		$456K Buy
136,820
+61,722
+82% +$165K ﹤0.01% 898
2023
Q3 		$281K Buy
+75,098
New +$347K ﹤0.01% 976
2021
Q2 		– Sell
-101,460
Closed -$1.48M – 1551
2021
Q1 		$1.48M Sell
101,460
-72,860
-42% -$1.24M 0.01% 732
2020
Q4 		$3.03M Sell
174,320
-1,400
-0.8% -$24.9K 0.01% 529
2020
Q3 		$3.22M Sell
175,720
-22,561
-11% -$420K 0.01% 431
2020
Q2 		$3.54M Buy
198,281
+33,133
+20% +$561K 0.02% 471
2020
Q1 		$2.68M Buy
165,148
+63,781
+63% +$1.18M 0.02% 466
2019
Q4 		$1.82M Buy
101,367
+74,987
+284% +$1.38M 0.01% 674
2019
Q3 		$534K Buy
+26,380
New +$527K ﹤0.01% 968

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Los Angeles Capital Management's CHRS Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Coherus Oncology (CHRS) in Q1 2026, closing a stake of 131,360 shares — an estimated $223K sold.

Los Angeles Capital Management first reported a position in CHRS in Q3 2019 and held it in 17 quarters. The position peaked at $3.54M in Q2 2020. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Coherus Oncology position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 131,360 Coherus Oncology shares in Q1 2026, an estimated $223K.
  • Los Angeles Capital Management first reported a position in Coherus Oncology in Q3 2019 and held it in 17 quarters.
  • Los Angeles Capital Management's Coherus Oncology position peaked at $3.54M in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.